Abstract
Recent changes in the healthcare system have prompted the growth and management of disease and health management strategies in the US. Most of the initiatives include a heavy emphasis on the pharmacotherapy component as it has been noted that effective therapies can lead to improvement in care and in some cases lower overall healthcare costs.
As markets continue to move to increased integration, there will be a greater focus on traditional pharmacy and therapeutic committees to evaluate the impact of therapies on the overall care of and cost to their covered members. Additionally, pharmaceutical products will be evaluated as to their place in the overall health and disease management strategies that the plan offers to its payers and providers.
A growing trend among pharmaceutical benefit designs is to offer various levels of coverage via patient copayments to reduce the growth of drug expenditures. This places a greater emphasis on provider communication and patient awareness and understanding of the value of pharmaceutical products as a means to improving health.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Todd WE, Eichert JH, Toscani MT. Disease management: building a solid foundation. Dis Manag Health Outcomes 1997; 1: 26–33
Meyer PR. The changing environment for US pharmaceuticals. Pharmacoeconomics 1994; 6 Suppl. 1: 80–4
National Managed Healthcare Congress. Disease management strategic research study and resource guide. Waltham (MA): National Managed Healthcare Congress Inc., 1996; 54–5
Sclar DA. Disease state management: an overview for the managed care pharmacist. Drug Benefit Trends 1995; 7(5): 8–16
Santell JP. Projecting future drug expenditures — 1996. Am J Health Syst Pharm 1996; 53: 139–50
Armstrong EP. Disease state management and its influence on health systems today. Drug Benefit Trends 1996; 8(7): 18–29
Summers KH, Szeinbach SL. Formularies: the role of pharmacy-and-therapeutics (P&T) committees. Clin Ther 1995; 15(2): 433–41
Novartis Pharmacy Benefit Report. Trends and forecasts. East Hanover (NJ): Novartis,1998
Horn SD, Sharkey PB, Tracey DM, et al. Intended and unintended consequences of HMO cost containment strategies: results from the managed care outcomes project. Am J Manag Care 1996; 2: 253–64
Curtiss FR. Drug formularies provide a path to best care. Am J Health Syst Pharm 1996; 53: 2201–3
Goldberg RB. Managing the pharmacy benefit: the formulary system. J Manag Care Pharm 1997; 3: 565–73
Cathey JT. The end of the restricted formulary? Drug Benefit Trends 1996; 8: 4
Toscani M. Moving toward a health management system. Concepts in pharmacoeconomics, pharmacoeconomics and outcomes — applications for patient care. Am Coll Clin Pharm 1996; 1: 23–6
Todd WE, McFarland T. Choosing a disease management strategy. Drug Benefit Trends 1998; 3: 1–7
Couch JB. Is prescription management keeping pace with the evolving need to demonstrate value? Drug Benefit Trends 1998; 10(4): 39–45
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Toscani, M., Suh, D.C. & Benedict, B. Impact of Disease and Health Management Strategies on Formulary Design and Management. Dis-Manage-Health-Outcomes 8, 1–7 (2000). https://doi.org/10.2165/00115677-200008010-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00115677-200008010-00001